Health Policy

Mission Statement

The Health Policy Working Group was founded in May 2015 upon unanimous decision of the AIPES General Assembly.

Health policy decisions are heavily influencing business development in molecular imaging in Europe. Rapidly increasing requirements of the notifying bodies make it more and more difficult to enter the molecular imaging market in a timely fashion.
Diagnostic and therapeutic procedures today have to demonstrate clinical evidence, economic and societal value before obtaining reimbursement.
Health economic analysis are a becoming a crucial part of the evaluation process also for radiopharmaceuticals to obtain reimbursement.
Reimbursement of new and existing technologies in molecular imaging is key to business success.

  • The mission of the working group Health Policy is to strengthen Health Policy and Market Access knowledge and activities at a European level and advise the members regarding products or procedures reimbursement and healthcare funding
  • The Health Policy Working Group is committed to promote the generation of scientific evidence in Molecular Imaging and Nuclear Medicine to be used by the health policy decision makers
  • The Group will produce and/or gather presentation materials demonstrating the benefits of Nuclear Medicine for the patient communities and the Health Care budgets of the Members States. Thereby, together with its members, the Group will participate and collaborate actively in evidence generating studies and activities
  • It engages in creating visibility and full understanding at health policy level regarding molecular imaging with the European Institutions
  • The Health Policy Working Group provides medical evidence to the other Working Groups of AIPES when appropriate.